Sudarshan Pharma [SUDARSHAN] vs Navin Fluorine [NAVINFLUOR] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sudarshan Pharma Industries Ltd. wins in 7 metrics, Navin Fluorine International Ltd. wins in 11 metrics, with 0 ties. Navin Fluorine International Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sudarshan Pharma Industries Ltd. | Navin Fluorine International Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 35.73 | 57.84 | Sudarshan Pharma Industries Ltd. |
| Price-to-Book Ratio | 5.61 | 8.89 | Sudarshan Pharma Industries Ltd. |
| Debt-to-Equity Ratio | 155.50 | 32.68 | Navin Fluorine International Ltd. |
| PEG Ratio | N/A | 0.28 | N/A |
| EV/EBITDA | 20.44 | 35.28 | Sudarshan Pharma Industries Ltd. |
| Profit Margin (TTM) | 3.26% | 17.74% | Navin Fluorine International Ltd. |
| Operating Margin (TTM) | 5.93% | 30.42% | Navin Fluorine International Ltd. |
| EBITDA Margin (TTM) | 5.93% | 30.42% | Navin Fluorine International Ltd. |
| Return on Equity | 12.13% | 10.99% | Sudarshan Pharma Industries Ltd. |
| Return on Assets (TTM) | 3.96% | 5.97% | Navin Fluorine International Ltd. |
| Free Cash Flow (TTM) | $304.76M | $40.40M | Sudarshan Pharma Industries Ltd. |
| Dividend Yield | N/A | 0.22% | N/A |
| 1-Year Return | 19.22% | 67.30% | Navin Fluorine International Ltd. |
| Price-to-Sales Ratio (TTM) | 1.12 | 10.45 | Sudarshan Pharma Industries Ltd. |
| Enterprise Value | $9.53B | $329.73B | Navin Fluorine International Ltd. |
| EV/Revenue Ratio | 1.48 | 10.72 | Sudarshan Pharma Industries Ltd. |
| Gross Profit Margin (TTM) | 12.03% | 58.79% | Navin Fluorine International Ltd. |
| Revenue per Share (TTM) | $26 | $611 | Navin Fluorine International Ltd. |
| Earnings per Share (Diluted) | $0.84 | $108.35 | Navin Fluorine International Ltd. |
| Beta (Stock Volatility) | 0.69 | 0.23 | Navin Fluorine International Ltd. |
Sudarshan Pharma Industries Ltd. vs Navin Fluorine International Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sudarshan Pharma Industries Ltd. | 0.29% | -6.63% | 10.91% | 32.55% | 30.44% | 27.16% |
| Navin Fluorine International Ltd. | 0.78% | -2.88% | 3.52% | 15.79% | 20.71% | 18.59% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sudarshan Pharma Industries Ltd. | 19.22% | 423.13% | 459.90% | 459.90% | 459.90% | 459.90% |
| Navin Fluorine International Ltd. | 67.30% | 54.46% | 123.78% | 1,600.30% | 12,289.64% | 10,949.29% |
Performance & Financial Health Analysis: Sudarshan Pharma Industries Ltd. vs Navin Fluorine International Ltd.
| Metric | SUDARSHAN | NAVINFLUOR |
|---|---|---|
| Market Information | ||
| Market Cap | ₹7.29B | ₹322.36B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 307,600 | 159,766 |
| 90 Day Avg. Volume | 248,667 | 161,398 |
| Last Close | ₹34.47 | ₹7,090.50 |
| 52 Week Range | ₹18.50 - ₹36.95 | ₹4,348.20 - ₹7,525.00 |
| % from 52W High | -6.71% | -5.77% |
| All-Time High | ₹452.70 (Sep 30, 2024) | ₹7,525.00 (May 26, 2026) |
| % from All-Time High | -92.39% | -5.77% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.45% | 0.47% |
| Quarterly Earnings Growth | 0.51% | 1.22% |
| Financial Health | ||
| Profit Margin (TTM) | 0.03% | 0.18% |
| Operating Margin (TTM) | 0.06% | 0.30% |
| Return on Equity (TTM) | 0.12% | 0.11% |
| Debt to Equity (MRQ) | 155.50 | 32.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹5.35 | ₹705.31 |
| Cash per Share (MRQ) | ₹0.11 | ₹168.63 |
| Operating Cash Flow (TTM) | ₹8.46M | ₹4.60B |
| Levered Free Cash Flow (TTM) | ₹159.55M | ₹2.89B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.22% |
| Last 12-Month Dividend | N/A | ₹13.50 |
Valuation & Enterprise Metrics Analysis: Sudarshan Pharma Industries Ltd. vs Navin Fluorine International Ltd.
| Metric | SUDARSHAN (Apr 24, 2026) | NAVINFLUOR (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 35.73 | 57.84 |
| Forward P/E | N/A | 42.34 |
| PEG Ratio | N/A | 0.28 |
| Price to Sales (TTM) | 1.12 | 10.45 |
| Price to Book (MRQ) | 5.61 | 8.89 |
| Market Capitalization | ||
| Market Capitalization | ₹7.29B | ₹322.36B |
| Enterprise Value | ₹9.53B | ₹329.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.48 | 10.72 |
| Enterprise to EBITDA | 20.44 | 35.28 |
| Risk & Other Metrics | ||
| Beta | 0.69 | 0.23 |
| Book Value per Share (MRQ) | ₹5.35 | ₹705.31 |
Financial Statements Comparison: Sudarshan Pharma Industries Ltd. vs Navin Fluorine International Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | SUDARSHAN (2025) | NAVINFLUOR (2025) |
|---|---|---|
| Revenue/Sales | 5.05B | 23.30B |
| Cost of Goods Sold | 4.40B | 11.02B |
| COGS % of Revenue | 87.1% | 47.3% |
| Gross Profit | 651.01M | 12.27B |
| Gross Margin | 12.9% | 52.7% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 379.01M | 4.14B |
| Operating Margin | 7.5% | 17.8% |
| EBITDA | 407.72M | 5.51B |
| EBITDA Margin | 8.1% | 23.7% |
| Pre-Tax Income | 216.29M | 3.80B |
| Pre-Tax Income % of Revenue | 4.3% | 16.3% |
| Income Tax | 56.77M | 914.90M |
| Income Tax % of Revenue | 1.1% | 3.9% |
| Net Income (Profit) | 159.53M | 2.89B |
| Profit Margin | 3.2% | 12.4% |
Balance Sheet & Liquidity Metrics
| Metric | SUDARSHAN (2025) | NAVINFLUOR (2025) |
|---|---|---|
| Cash & Equivalents | 5.51M | 196.80M |
| Total Current Assets | 3.35B | 15.89B |
| Total Current Assets % of Revenue | 66.3% | 68.2% |
| Total Current Liabilities | 2.60B | 9.15B |
| Total Current Liabilities % of Revenue | 51.4% | 39.3% |
| Long-Term Debt | 104.60M | 10.67B |
| Long-Term Debt % of Revenue | 2.1% | 45.8% |
| Total Shareholders Equity | 1.31B | 26.26B |
| Retained Earnings | N/A | 23.27B |
| Retained Earnings % of Revenue | 0.0% | 99.9% |
| Property, Plant & Equipment | 200.50M | 25.97B |
Cash Flow Statement Comparison
| Metric | SUDARSHAN (2025) | NAVINFLUOR (2025) |
|---|---|---|
| Operating Cash Flow | 8.46M | 4.60B |
| Operating Cash Flow % of Revenue | 0.2% | 19.7% |
| Capital Expenditures | -47.46M | -5.61B |
| Free Cash Flow | 304.76M | 40.40M |
| FCF Margin | 6.0% | 0.2% |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUDARSHAN | NAVINFLUOR |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 240.66M | 51.24M |
| Float Shares | 87.72M | 36.18M |
| % Held by Insiders | 76.52% | 29.38% |
| % Held by Institutions | 0.00% | 39.84% |
| % Held by Public | 23.48% | 30.78% |
Dividend Analysis & Yield Comparison: Sudarshan Pharma Industries Ltd. vs Navin Fluorine International Ltd.
| Metric | SUDARSHAN | NAVINFLUOR |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹13.50 |
| Last 12-Month Dividend Yield | N/A | 0.22% |
| 3-Year Avg Annual Dividend | N/A | ₹15.83 |
| 3-Year Avg Dividend Yield | N/A | 0.16% |
| 3-Year Total Dividends | N/A | ₹47.50 |
| Ex-Dividend Date | N/A | Nov 07, 2025 |